Diabetics with Hyperkalimia is usually associated with Chronic Kidney Disease. Metformin which is renal toxic would had been stopped at this time and replaced with a DPP-4 inhibitor (Onglyza, Tradjenta, or Januvia), a TZD , a sulfonyurea or insulin. So Metformin wouldn't be a big issue.
Send them in boys. We got $75, 75, 75. $80, we got $80, 80, 80...$90 !!! 90, 90, 90.... Don't ask your wife, you won't get nothing.. Keep 'em coming boys. Do I hear $100? A $100, 100, 100...
If no one is buying, Why did it stop around @20 PPS? It should go to $10 or $5 or $0... This is called MANIPULATION. BO is coming. This happened to me with CHTP and ITMN. There's always a big drop before the buyout announcement.
It's possible that announcement of BO maybe in the next 7 days. They usually want to close the deal at the launch date which is about 4-5 weeks. The biggest surprise is not whether there will be a buyout but at what price. And it's not $30 PPS. It could be 2X that makes it $60 PPS. I say 3X that. So $90-95 PPS.
You better cover and go long. You can still recover all your losses. This will open huge Monday. Announcement is after the bell or sunday night. $95 PPS. This will break you.
FDA Approves Potassium-Binder Patiromer (Veltassa), New Option for RAAS-Inhibitor–Treated Patients.
"After Dr Bertram Pitt (University of Michigan, Ann Arbor) presented the trial at the American College of Cardiology 2015 Scientific Sessions, he told heart wire from Medscape that after the supposed approval of patiromer, and if another investigational potassium-binding agent, ZS-9 (ZS Pharma) is approved, "it looks like there is a new era . . . for renal disease and HF that really will change the game."
new era? wow !! And Patiromer is the only one FDA approved. ZS-9 is 6 months away.
Launch is in 4-5 weeks. Expect a Buyout before then.
Merry Christmas longs .
Fact is ZS-9 is not FDA approved. Anything can happen between now and D-day. Lots of questions to be answered. And $65 PPS for a company that doesn't have any approved drug. This will be a heavily shorted drug in the coming weeks and months.
medical students, residents, and newbie doctors for didactic purposes and mental musterbation. Experienced physicians will be writing for Veltassa without any problems.